pharmacie et médicaments – Traitements anti-obésité de type GLP-1

This written question concerns obesity treatments, specifically those using GLP-1 agonists. It seeks information on the availability, cost, and accessibility of these medications within the French healthcare system. The question addresses the impact on patients, healthcare providers, and the pharmaceutical industry, potentially influencing future drug pricing and reimbursement policies.